Another guideline about Rivaroxaban. Guidance was published in 2012 advising that Rivaroxaban could be used in the treatment of DVT. At that point, there was no guidance about its use in PEs. Since then a study has shown that it is as effective as Warfarin in the treatment of PE. Therefore this new guideline advises that Rivaroxaban can be used in the treatment of PE and for the prevention of recurrent PE and DVT.
Its main advantage is that it does not need monitoring. Its main disadvantage is that its effects are not easily reversible. It is also expensive.